DarioHealth (NASDAQ:DRIO) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of DarioHealth (NASDAQ:DRIO – Free Report) to a hold rating in a report published on Saturday,Wall Street Zen reports.

DRIO has been the topic of several other research reports. Stifel Nicolaus decreased their price target on DarioHealth to $5.00 and set a “buy” rating on the stock in a report on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. BTIG Research began coverage on shares of DarioHealth in a research note on Tuesday, October 27th. They issued a “buy” rating and a $6.00 target price on the stock. Alliance Global Partners began coverage on shares of DarioHealth in a report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price for the company. Finally, TD Cowen lowered their target price on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DarioHealth currently has a consensus rating of “Hold” and an average price target of $7.75.

View Our Latest Research Report on DRIO

DarioHealth Trading Down 23.6%

DRIO traded down $0.39 on Friday, hitting $1.26. The company had a trading volume of 74,793 shares, compared to its average volume of 86,340. The business’s fifty day simple moving average is $5.03 and its 200 day simple moving average is $7.32. The company has a quick ratio of 1.92, a current ratio of 2.31 and a debt-to-equity ratio of 0.56. DarioHealth has a 12-month low of $1.26 and a 12-month high of $14.77. The company has a market cap of $12.35 million, a PE ratio of -0.32 and a beta of 1.18.

DarioHealth (NASDAQ:DRIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.22. The business had revenue of $5.31 million for the quarter, compared to the consensus estimate of $5.21 million. DarioHealth had a negative return on equity of 55.10% and a negative net margin of 159.85%. Equities research analysts expect that DarioHealth will post -2.94 EPS for the current year.

Institutional Investors Weigh In On DarioHealth

Institutional investors and hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC purchased a new position in DarioHealth during the 3rd quarter valued at $159,000. BlackRock Inc. purchased a new stake in DarioHealth in the second quarter worth $249,000. Finally, Nantahala Capital Management LLC purchased a new stake in DarioHealth in the second quarter worth $4,030,561. 33.39% of the stock is owned by institutional investors.

Key Headlines Impacting DarioHealth

Investors following DRIO have been watching these headlines:

  • Positive Sentiment: Management said contracted and late-stage annual recurring revenue totaled $13.1 million across more than 180 accounts, with over 80% tied to multi-condition opportunities. It expects revenue growth to accelerate late in 2026 and into 2027 as committed ARR converts, and cited a new New Jersey health-plan customer covering 1.5 million people. DarioHealth Q3 results
  • Positive Sentiment: Stifel Nicolaus lowered its price target to $5 but maintained a Buy rating, indicating that the analyst still sees substantial potential upside from the referenced share price. Stifel Nicolaus ratings
  • Neutral Sentiment: Despite the improving operating trends, DarioHealth remains loss-making, and GAAP gross margin edged down to 59% from 60% a year earlier. The forecasted growth depends on converting contracted and late-stage opportunities, so execution and the timing of revenue remain key risks. DarioHealth Q3 results

DarioHealth Company Profile

(Get Free Report)

DarioHealth Corp. is a digital health company that develops technology-enabled programs to help people manage chronic and behavioral health conditions. Its offerings combine mobile applications, connected devices, coaching and personalized guidance. The company’s services address conditions including diabetes, hypertension, weight management, musculoskeletal health and behavioral health. Its platform is designed to support individuals as well as employers and health plans seeking to provide digital health programs to their members.

Further Reading

Analyst Recommendations for DarioHealth (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.